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Atrial ﬁbrillationAbstract Background: Atrial ﬁbrillation (AF) is considered the major cause of stroke in the
elderly. Alternative therapies to the anticoagulant therapy are warranted, particularly in patients
who are ineligible or at high risk of bleeding. The left atrial appendage (LAA) is a prominent source
of thrombi in nonvalvular AF, accounting for 90% of thrombi. As a result, surgical and tran-
scatheter techniques have been explored to reduce the risk of stroke in patients with AF by occlud-
ing the LAA.
Objectives: To assess the safety and efﬁcacy of LAA closure in patients with nonvalvular atrial ﬁb-
rillation (AF) ineligible for warfarin therapy.
Methods: A prospective study that evaluated LAA closure with the Watchman device (Boston
Scientiﬁc, Natick, MA; group A) in ﬁfteen patients with nonvalvular AF and CHADS2 (congestive
heart failure, hypertension, ageP75 years, diabetes mellitus, and prior stroke or transient ischemic
attack) score P1, who were considered ineligible for warfarin therapy. The primary efﬁcacy end-
point was the combined events of ischemic/hemorrhagic stroke, systemic embolism and cardiovas-
cular/unexplained death during a period of six months follow-up.
Results: Successful closure of the LAA using the Watchman device was achieved in 15 patients
(100%). The mean age was found to be 67.9 ± 9 years with 40% of them being males. No device
or procedure related adverse events were detected. The mean CHADS2 score was 2.4 ± 0.8, while
the mean CHA2DS2-VASC score was 4.4 ± 1.0. After a mean period of 8 ± 2 months of follow-
up, no device dislodgement or device-related thrombi were documented. The all-cause stroke
(ischemic and hemorrhagic) and systemic embolism were 0%. The device and procedure related
mortality was found to be 0%. Only one patient died after 8 months of device implantation from
pneumonia.
24 H. Khamis et al.Conclusion: LAA closure with the Watchman device can be safely performed, and may be a rea-
sonable alternative to consider for patients at high risk for stroke but with contraindications to sys-
temic oral anticoagulation or with high risk of bleeding.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained arrhyth-
mia, and increases the risk of ischemic stroke 5-fold. AF-
related ischemic stroke is associated with signiﬁcant morbidity,
mortality, and healthcare expenditures. Thus, prevention of
cardioembolic stroke has a paramount clinical and economical
importance.1–5
The left atrial appendage (LAA) has found considerable
attention as a cause of cardioembolic stroke and echocardio-
graphic studies have long documented spontaneous echo con-
trast or ‘smoke’ that indicates intracavitary blood stasis.
Blackshear and Odel reviewed 23 studies that included patients
with rheumatic and nonrheumatic atrial ﬁbrillation. Distinct
differences were noted in the frequency and distribution of
LAA thrombus. In non-rheumatic atrial ﬁbrillation, 91% of
left atrial thrombi were isolated to or had originated in the
LAA.6
This pathophysiology led to the widespread use of antico-
agulant therapy, initially with warfarin, which has been proven
to be superior to aspirin for stroke prevention.7 Multiple prob-
lems with warfarin have been identiﬁed, including bleeding,
contraindications to its application, patient compliance, and
the need for routine monitoring. Thus, it is estimated that anti-
coagulation is not currently used in up to 50% of eligible AF
patients, which led to the development of new oral anticoagu-
lants (NOACs), whose efﬁcacy has been established in ran-
domized clinical trials.
The risk of bleeding with approved doses of NOACs is
either similar to warfarin, or, in the case of apixaban, lower,
but rivaroxaban and dabigatran had an increased risk of gas-
trointestinal bleeding. In older patients or those with renal dys-
function, the bleeding risks associated with dabigatran were
equal or greater than warfarin. This bleeding risk, combined
with the perceived absolute or relative contraindications by
the patient or physician, as well as issues with long-term com-
pliance, cost, and the lack of widely available antidotes, repre-
sents substantial challenges for the management of stroke
prevention in patients with AF.8–10
As an alternative to systemic anticoagulant therapy, the
PROTECT AF (Watchman Left Atrial Appendage System
for Embolic Protection in Patients With AF) clinical trial
examined the hypothesis that the ‘‘local’’ therapy of left atrial
appendage (LAA) closure could achieve the beneﬁts in stroke
prevention observed with warfarin.11
The Watchman device proved to be noninferior to warfarin
in preventing stroke in nonvalvular AF patients with a
CHADS2 (congestive heart failure, hypertension, age
P75 years, diabetes mellitus, and prior stroke or transient
ischemic attack) score P1. However, PROTECT AF only
included patients who were candidates for either therapy,
and in patients randomized to the LAA closure arm, patientsreceived concomitant warfarin after Watchman implantation
for 6 weeks.11,122. Aim of the study
The aim of this study was to evaluate the feasibility, safety and
efﬁcacy of transcatheter left atrial appendage (LAA) closure
using the Watchman device in patients with nonvalvular atrial
ﬁbrillation (AF) especially those who were considered ineligi-
ble for anticoagulant therapy or had high bleeding risk.3. Methodology
3.1. Study design and patients
A prospective registry included ﬁfteen patients with nonvalvu-
lar atrial ﬁbrillation ineligible for long term anticoagulant
therapy or with high bleeding risk. LAA closure using
the Watchman device was performed for all enrolled patients
followed by at least 6 months follow-up.
 Inclusion criteria:
– Patients with nonvalvular AF (paroxysmal, persistent or
permanent).
– Age > 18 years.
– CHADS2 score P1
– Patients with a contraindication for long term oral anti-
coagulation therapy or with a high risk of bleeding as
indicated by the presence of at least one of the following
criteria:HAS-BLED score P3
Prior bleeding complication while using warfarin.
Major bleeding prior to using warfarin leading to
markedly elevated risk of recurrence.
Walking instability with recurrent falls.
Inability to maintain INR levels within the therapeu-
tic range with warfarin.
– Patients who were able to verbally conﬁrm understand-
ing of risks, beneﬁts and treatment alternatives of receiv-
ing left atrial appendage closure with the Watchman
device and he/she or his/her legally authorized represen-
tative provided written informed consent prior to any
related procedure.
– Patients must agree to undergo all investigation plan
required.
 Exclusion criteria:
– Intracardiac thrombus detected by transesophageal
echocardiography (TEE).
– An existing pericardial effusion >3 mm.
re 253.2. Study deviceThe WATCHMAN device (Boston Scientiﬁc, Natick,
Massachusetts) has a self expanding, open-ended, nitinol cage
with tines to anchor the device in place. The body of the
device, speciﬁcally the aspect exposed to the left atrium, is cov-
ered in a permeable polytetraﬂuoroethylene (PET). It comes in
sizes of 21, 24, 27, 30, and 33 mm, and the appropriate device
is chosen to be 2–4 mm greater than the maximum LAA
ostium diameter.11
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– Baseline transoesophageal echocardiography (TEE) was
performed to assess the shape, size, and location of the
appendage. LAA thrombus and pericardial effusion had
to be excluded. The LAA length and ostial diameter were
measured (must be between 17 and 31 mm).
– Under sedation anesthesia, TEE and ﬂuoroscopic guidance,
Watchman implantation was performed through traditional
transseptal puncture and the Amplatz superstiff guidewire
(Boston scientiﬁc) was positioned in the left upper pul-
monary vein to be used as a rail. Anticoagulation was
started immediately after transseptal puncture using hep-
arin to achieve active clotting time (ACT) between 200 s
and 300 s.11
– The device had to meet all four of the device release criteria,
abbreviated as PASS:
(1) Position: the plane of maximum diameter of the device
should be at or just distal to the LAA ostium and span it com-
pletely. The position is conﬁrmed via TEE and ﬂuoroscopy. (2)
Anchor or stability: the AS/DC assembly is withdrawn a few
centimeters from the device. Gently pull back and then release
deployment knob. The device and LAA should move in uni-
son. Stability is conﬁrmed via TEE and ﬂuoroscopy. (3)
Size: the plane of maximum diameter of the device is measured
and should be 80–92% of the original size measured under
TEE. (4) Seal: all lobes must be distal to the device and sealed
under TEE. If any of the release criteria were not met, the
device could always be recaptured partially or completely.11
– After the procedure, patients had to remain on warfarin
(INR 2.0–3.0) and 81 mg aspirin for a minimum of 45 days
(except those with absolute contraindication for anticoagu-
lant therapy). Then, device placement was conﬁrmed with
TEE, patients discontinued warfarin and began clopidogrel
75 mg and aspirin daily for 6 months after implantation and
remained on daily aspirin indeﬁnitely.11 This regimen might
change according to the clinical situation as assessed by the
physician.
– Short term follow-up was done during hospitalization after
the procedure and included clinical examination, electro-
cardiography, transthoracic echocardiography (TTE) and
other needed investigations to detect any possible
complication.
– Long term follow-up was done for 6 months through
monthly visits. On each visit, the patient was subjected to
full clinical examination, TTE and any other investigation
needed based on history and physical examination. A
TEE was performed at 45 days and 6 months to assess
device position, peri-device LAA ﬂow, and device relatedthrombus. Neurological consultation was done on each visit
and any requested investigations were performed. The
National Institutes of Health stroke scale was administered
by a neurologist at baseline, 3 and 6 months.13
3.4. Deﬁnitions
– The CHADS2 score (scale 0–6) includes congestive heart
failure, hypertension, age P75 years, diabetes mellitus,
and prior stroke or transient ischemic attack (TIA [2
points]). The CHA2DS2-VASc score (scale 0–9) includes
the same components but with 2 points for age P75 years
and the addition of 1 point for vascular disease, age 65–
74 years, or female sex.14
– Contraindications for oral anticoagulant use (based on the
warfarin labeling) were categorized as follows:
 Hemorrhagic/bleeding tendencies deﬁned as active pep-
tic ulcer disease or history of overt bleeding of the gas-
trointestinal, genitourinary, or respiratory tract; central
nervous system hemorrhage, cerebral aneurysms, dissec-
tion of the aorta, pericarditis/pericardial effusions or
bacterial endocarditis.
 Blood dyscrasias.
 Unsupervised patients with senility and/or high fall risk.
 Other documented reason (including hypersensitivity to
warfarin).
– The composite primary efﬁcacy endpoint included ischemic
stroke, hemorrhagic stroke, systemic embolism, cardiovas-
cular or unexplained death. The composite primary safety
endpoint included the occurrence of death, bleeding, proce-
dure or device-related events e.g. pericardial effusion, stroke
or device embolization within 7 days of the procedure.
– A serious adverse event included any untoward medical
condition that resulted in death, was life-threatening,
required inpatient hospitalization or prolongation of exist-
ing hospitalization, required major cardiovascular or
endovascular intervention or resulted in persistent or signif-
icant disability/incapacity.
3.5. Statistical analysis
This is a feasibility study designed to provide preliminary
information on the performance of the Watchman LAA clo-
sure device in patients with nonvalvular AF. The sample size
was not deﬁned on the basis of an end-point hypothesis but
rather to provide information on device performance. For bin-
ary variables, percentages were calculated. When provided, the
95% conﬁdence intervals were computed with the gaussian
approximation, taking into account the paired analysis.
Paired comparisons between post-procedural and follow-up
results were done by a Wilcoxon signed-rank test.
4. Results
4.1. The baseline clinical characteristics
Demographic data, cardioembolic and bleeding risk factors of
patients enrolled in this study are listed in Table 1. The age of
Table 1 Baseline characteristics of the study population.
Demographic information
Age (yrs) 67.9 ± 9
Male (%) 40%
Stroke risk factors
Heart failure or reduced ejection fraction 20%
Hypertension 80%
AgeP 75 yrs 26.6%
Diabetes Mellitus 66.6%
Prior stroke or TIA 26.6%
Vascular disease 66.6%
Age 65–74 yrs 46.6%
Female 60%
Additional bleeding risk factors
Abnormal renal function 33.3%
Abnormal liver function 13.3%
Bleeding tendency 53.3%
Labile INR 13.3%
Drug therapy (that increases risk of bleeding) 73.3%




Score Patients (%) Score Patients (%) Score Patients (%)
1 6.6 1 0 1 0
2 53.3 2 0 2 13.3
3 26.6 3 13.3 3 40
4 13.3 4 46.6 4 3.33
5 0 5 26.6 5 13.3
6 0 6 6.6 6 0
7 6.6 7 0
8 0 8 0
9 0 9 0
Mean CHADS2





score 3.4 ± 0.9
26 H. Khamis et al.the study population ranged from 57 to 84 years with a mean
of 67.9 ± 9 years, and 40% of them were males. The most
common risk factor for stroke was hypertension (80%), and
26.6% of patients previously had an ischemic stroke/TIA.
Only two patients had paroxysmal AF and all other patients
had permanent AF. These patients were selected after screen-
ing of 42 patients. The excluded patients did not meet the
inclusion criteria especially being ineligible for long term anti-
coagulant therapy or refusing device implantation (see Fig. 1).
The mean CHADS2 score was found to be 2.4 ± 0.8, and
93.2% of patients had a CHADS2 score P2. However, the
mean CHA2DS2-VASC score was 4.4 ± 1.0 and all patients
had a CHA2DS2-VASC score P2. High bleeding risk (HAS-
BLED score P3) was estimated in 86.6% of the enrolled
patients (Table 2 and Fig. 2).
High (HAS-BLED Score) was the most common reason for
device implantation (86.6%). Moreover, nine patients (60%)
had history of previous bleeding (2 cerebral, 3 gastrointestinal,
2 urinary tract, 1 piles and 1 subcutaneous hemorrhage). In
addition, three patients had unsupervised senility and high fall
risk (20%), and one patient suffered from thromboembolismFigure 1 The Watdespite target INR (6.7%) (Fig. 3). It should be noted that
some patient had more than one indication for LAA occlusion.
4.2. The procedural details
The procedural details are listed in Table 3. The mean proce-
dure time was 56.8 ± 10 min. Successful device implantation
was done in all patients (100%). Difﬁcult implantation
occurred in only one patient due to anatomical considerations
(cauliﬂower LAA with a large oval ostium), and the device was
introduced but did not meet the device release criteria.
Therefore, partial recapture was done and the device was repo-
sitioned and successfully deployed. The majority of implanted
devices (73.3%) were either 24 mm or 27 mm in size (Table 3
and Fig. 4). No procedure or device related adverse events
were noted during the procedure or during post-procedural
hospitalization apart from a small inguinal hematoma in one
patient related to the femoral access that resolved completely
after 48 h without requiring any surgical interference.
4.3. The anti-thrombotic medication regimen
The majority of cases (87%) received warfarin prior to device
implantation. Aspirin and warfarin were administered duringchman device.12








0% 20% 40% 60% 80% 100%
Unsupervised Senility / high fall risk …
Labile INR
Bleeding from other sites …
Hisory of GIT bleeding
Hisory of cerebral Hge
Thromboembolism despite Target INR
High HASBLED score ≥ 3
Figure 3 Indications for Watchman device implantation. It worth noting that some patients had more than one indication for LAA
occlusion.
Table 3 The procedural details.
Procedural details
Procedure time 56.8 ± 10 (44–82) min
Implant success 15 patients (100%)
Implanted device sizes










Percentage of implanted devices according to device size






Figure 4 Implanted device sizes.
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Afterward, aspirin and plavix were given till 6 months in
87% of cases and then aspirin was taken indeﬁnitely by 80%
of patients (Table 4 and Fig. 5).4.4. Follow-up outcomes
The mean duration of follow-up was 8 ± 2 months, and the
overall compliance with follow-up visits was 100%. Clinical
follow-up revealed no device or procedure related adverse
events. Furthermore, all-cause stroke (ischemic and hemor-
rhagic) and systemic embolism were not documented in any
patient (0%). No device or procedure related mortality has
been observed. Only one patient died 8 months after device
implantation from pneumonia (he was 53 years old, had previ-
ous multiple strokes despite optimum anticoagulation and was
bed ridden) (see Fig. 6).
Transesophageal echocardiographic follow-up showed well
positioned device in all patients with no dislodgement or device
related thrombus. A nonsigniﬁcant leak (3 mm) was observed
in only one patient.5. Discussion
This study reports, for the ﬁrst time in Egyptian patients,
high acute implantation success rates of Watchman LAA
closure system despite variable anatomy and different device
sizes in conjunction with an acceptable procedural risk.
Importantly, the vast majority of the ‘‘high risk’’ patients
included in our registry was able to switch to ‘‘stand alone’’
ASA therapy after 6 weeks of combined anticoagulation
therapy without any increase in the incidence of stroke or
systemic embolization.
Table 4 Antithrombotic medications.









ASA+ Plavix +Marevan 2 (13%) 1 (7%) 0 (0%) 0%
ASA+ Plavix 2 (13%) 1 (7%) 13 (87%) 1 (7%)
ASA+Marevan 7 (47%) 11 (73%) 0 (0%) 0 (0%)
Marevan 4 (27%) 0 (0%) 0 (0%) 0 (0%)
ASA 0 (0%) 0 (0%) 0 (0%) 12 (80%)































Figure 5 Antithrombotic medications.
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The ﬁrst prospective, randomized trial investigating
Watchman LAA closure device was PROTECT AF trial in
which 707 patients with NVAF were randomly assigned in aFigure 6 Imaging guidance d2:1 ratio to either percutaneous LAA occlusion with the
WATCHMAN device or to warfarin therapy. The study was
designed to assess the non-inferiority of the device against
chronic OAC therapy. Patients with paroxysmal, persistent
or permanent NVAF were eligible for enrollment if they had
a CHADS2 risk score P1. The trial conﬁrmed the non-
inferiority of WATCHMAN LAA occlusion compared with
OAC therapy regarding the primary efﬁcacy endpoint––a com-
posite of stroke, systemic embolism and cardiovascular death
(RR= 0.62, 95% CI 0.35–1.25). The probability of non-
inferiority of the intervention was >99.9%.11
However, Protect AF included ‘‘nonhigh risk’’ stroke
patients and all patients were still eligible to OAC and there-
fore continued warfarin for at least 45 days after the
procedure.
In our registry, in contrast to Protect AF trial, the mean
CHA2DS2-VASC score was 4.4 ± 1.0 and all patients had a
CHA2DS2-VASC scoreP 2. High bleeding risk (HAS-
BLED scoreP 3) was estimated in 86.6% of the enrolled
patients. The expected annual risk of stroke based on the
CHADS2 score in our study cohort was calculated to beuring device implantation.
Safety and efﬁcacy of transcatheter left atrial appendage closure 294.9%/year and 2.4%/6 months. In contrast, no strokes have
occurred in any of the patients in this study despite discontin-
uation of anticoagulation in all patients after 45 days and an
average follow-up of 8 ± 2 months.
It is also of particular interest that in Protect AF, acute
device implantation failed in 9% (41/449 patients) due to var-
ious reasons but Watchman device implantation has been
reported to be difﬁcult in speciﬁc LAA anatomies such as a
shallow landing zones. It has also been recognized that human
LAA anatomy may be highly variable. Multiple lobes and
short LAA diameters may negatively impact successful LAA
occluder positioning and implantation.
Contrary to Protect AF, several recent registries including
those performed by Kim et al.15 and Swaans et al.16 reported
100% success rate of device implantation with better utilization
of imaging modalities and careful selection of device size as well
as the effect of progressive learning curve of the operators. In our
registry as well, the device was implanted successfully in all of
our patients. Notably, the procedure time declined gradually
with the increased experience of our operators.
5.2. Procedural safety and short-term outcome
In our registry no major device or procedure related adverse
events were observed. The all-cause stroke was estimated to
be 0% with no reported cases of device related mortality.
Only one patient died 8 months after the procedure due to
pneumonia without any device related complications.
In the pivotal PROTECTAF trial, an early safety hazardwas
identiﬁed: an increase in peri-procedural events of pericardial
effusions, which did not result in mortality but only prolonged
hospital stay. A risk for peri-procedural stroke was also identi-
ﬁed, usually the result of air embolization during catheter place-
ment. Longer term follow-up of PROTECT AF has conﬁrmed
the efﬁcacy of LAA occlusion. At a mean follow-up of
2.3 ± 1.1 years, the primary efﬁcacy endpoint remained non-
inferior for device (probability of non-inferiority >0.999).11
Within the early and late PROTECT AF experience, as well
as the CAP Registry, procedural/device related safety events
(including pericardial effusions) declined signiﬁcantly, suggest-
ing that the procedural safety of Watchman implantation
improved with increasing experience.12
The more recent PREVAIL (Prospective Randomized
Evaluation of the Watchman LAA Closure Device In
Patients With Atrial Fibrillation versus Long Term Warfarin
Therapy) documented the following ﬁndings in patients with
NVAF at risk for stroke: (1) procedural complications occur-
ring after Watchman LAA occlusion were infrequent and sig-
niﬁcantly improved compared with the PROTECT AF trial;
(2) Watchman LAA occlusion was non-inferior to chronic
warfarin for the prevention of stroke and SE beginning 1 week
after randomization, consistent with the hypothesis that the
LAA is the nidus for embolism in AF; and (3) the primary efﬁ-
cacy endpoint of early and late events was similar and did not
achieve non-inferiority with the Watchman device. Overall
event rates were lower than expected, which may have con-
tributed to this last ﬁnding.17
The lower rates of periprocedural major adverse events in
recent trial as well as our registry can be ascribed to a better
understanding of the procedure and an operator learning curve
effect.5.3. Post-procedural considerations and anti-coagulant regimens
Various antithrombotic regimens have been used after LAA
closure. In the PROTECT AF trial, OAC was given for
45 days and patients discontinued OAC if the 45-day TEE con-
trol showed either complete closure of the LAA or if the jet
width of the residual peridevice ﬂow was <5 mm. After stop-
ping OAC therapy, patients were given dual antiplatelet ther-
apy (DAPT) with acetylsalicylic acid (ASA) and clopidogrel
until completion of the 6-month TEE control, after which
ASA monotherapy was continued indeﬁnitely. In 14% of
patients, OAC was continued beyond 45 days, and in 8%
of patients, OAC was continued beyond 6 months because of
incomplete LAA closure or device thrombosis.11
Nevertheless, PROTECT AF trial did not address the
safety and efﬁcacy of LAA occlusion in patients with a high
thromboembolic risk (CHA2DS2-VASc score of >2) in whom
anticoagulation is believed to be either relatively or absolutely
contraindicated. Hence, our registry included this important
category of the AF patients and represents the ﬁrst prospective
study of LAA closure with the Watchman device in the clini-
cally important population of Egyptian patients with nonva-
lvular AF who are ineligible for oral anticoagulation therapy
or with high risk of bleeding.
It is worth mentioning that, although 80% of our patients
received warfarin for the ﬁrst 45 days after the device implan-
tation, 20% of cases received only antiplatelet therapy (13%
dual antiplatelet therapy and 7% clopidogrel alone) due to
contraindication to warfarin. Notably, the clinical outcome
did not show a signiﬁcant difference with no reported strokes
or systemic embolization events, which may explicit the device
efﬁcacy even in the absence of anticoagulant therapy following
implantation.
A population similar to ours was evaluated in the observa-
tional ASAP (ASA Plavix Feasibility Study With Watchman
Left Atrial Appendage Closure Technology) study, a multicen-
ter, prospective, nonrandomized study which included 150
patients with nonvalvular AF and CHADS2 scoreP 1, who
were considered ineligible for warfarin therapy. The study
reported that WATCHMAN implantation can be safely per-
formed without OAC transition and that DAPT prescribed
for 6 months followed by ASA alone may be an adequate
antithrombotic regimen.18
It should be noted that dual antiplatelet therapy (DAPT)
when given for 6 months followed by lifelong single antiplate-
let therapy, generates a major bleeding risk comparable to that
of warfarin.19 However, DAPT exposure following LAA
occlusion is only for short time, thus reducing the cumulative
risk of major bleeding events. In our registry cohort, DAPT
was abandoned after 6 months in 93% of cases, and single
antiplatelet therapy was continued (aspirin or clopidogrel in
80% and 13% of cases respectively).
Although 13% of patients in our study continued DAPT
for longer periods due to other indications (i.e. coronary artery
disease and recent PCI using DES), this strategy (LAA closure
plus DAPT) was supposed to offer less bleeding risk than using
triple antithrombotic therapy (warfarin plus DAPT) and more
thromboembolic protection than using DAPT alone, taking
into consideration that this speciﬁc group of patients had high
both thromboembolic and bleeding risks according to the
CHADS2-VASc and HAS-BLED scores.20,21 Eventually, this
30 H. Khamis et al.strategy resulted in neither increase in ischemic events nor
increase in bleeding complications.
5.4. TEE follow-up and the impact of residual peridevice leaks
Transesophageal echocardiographic follow-up in our registry
showed well positioned device in all patients with no dislodge-
ment or device related thrombus. A nonsigniﬁcant leak (3 mm)
was observed in only one patient.
Peridevice leaks are typically evaluated by color Doppler
(TEE) and classiﬁed as follows: (1) severe––multiple jets or free
ﬂow; (2) major––jet width > 3 mm; (3) moderate––jet width of
1–3 mm and (4) minor––jet width <1 mm. Major residual
leaks have been reported in as many as 32% of the patients
after WATCHMAN device implantation. Most importantly,
however, the presence of residual peridevice leaks has never
been associated with cardioembolic events in any of
Watchman studies.226. Study limitations
This study was a non-randomized feasibility trial primarily
designed to test the safety of the implantation procedure.
The study size was not intended to be of sufﬁcient power to
evaluate efﬁcacy. The absence of a control or alternative treat-
ment group and utilizing historical control data to predict the
expected stroke rates are considered another limitation.7. Conclusion
LAA occlusion with the WATCHMAN device appears to be
safe with preliminary results suggesting low stroke risk despite
discontinuation of anticoagulation. Thus, percutaneous LAA
occlusion can be considered as an alternative treatment strat-
egy to long-term anticoagulation for patients at greatest clini-
cal need for an alternative to oral anticoagulation therapy like
AF patients at high risk for stroke but with contraindications
to systemic oral anticoagulation or high bleeding risk.Conﬂict of interest
The authors declare that they have no conﬂict of interest.
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